- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
SRDX Market Currents
more »
-
May 8 SurModics (SRDX): Q1 EPS of $0.14 misses by $0.01. Revenue of $12.2M (-8.4% Y/Y). (PR)
Comment![Earnings, Healthcare]
SRDX in Focus
more »
SRDX Related Articles
more »
SRDX News
more »
-
at MarketWatch.com (May 9, 2012)
-
at MarketWatch.com (Feb 3, 2012)
-
at MarketWatch.com (Nov 2, 2011)
-
at MarketWatch.com (Aug 24, 2011)
-
at MarketWatch.com (Apr 28, 2011)
SRDX Press Releases and Filings
more »
-
Business Wire (Tue, 8:00AM)
-
Business Wire (May 14, 2012)
-
Business Wire (May 8, 2012)
-
Business Wire (Apr 25, 2012)
-
Business Wire (Apr 16, 2012)
SRDX Latest Transcript
more »
SRDX Cramer
more »
Currently, there are no Cramer articles on SRDX.
SRDX Instablog posts
more »
SRDX vs. ETF Alternatives
Company Description
SurModics, Inc. is a leading provider of drug delivery and surface modification technologies to the healthcare industry. Our mission is to exceed our customers’ expectations and enhance the well-being of patients by providing the world’s foremost, innovative drug delivery and surface... More
